Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547242 | 0.94 | ERN1 (0.40) | ACHEERN1HRH4HRH3TGM2 | |
| SCHEMBL3676772 | 0.88 | TGM2 (0.46) | ACHEERN1TGM2TSHREPHX2 | |
| SCHEMBL8832849 | 0.88 | MEN1 (0.39) | ACHEERN1HRH4HRH3MEN1 | |
| SCHEMBL24660419 | 0.86 | HRH4 (0.49) | ACHEERN1HRH4HRH3TGM2 | |
| SCHEMBL13055388 | 0.86 | MAPT (0.42) | ACHEERN1HRH4HRH3MEN1 | |
| SCHEMBL15809690 | 0.85 | ACHE (0.46) | ACHEERN1HRH4HRH3TGM2 | |
| SCHEMBL8833233 | 0.83 | ACHE (0.40) | ACHEERN1HRH4HRH3TGM2 | |
| SCHEMBL15109209 | 0.83 | ALDH1A1 (0.46) | ACHEERN1HRH4HRH3TGM2 | |
| SCHEMBL17489324 | 0.83 | ACHE (0.40) | ACHEERN1HRH4HRH3TGM2 | |
| SCHEMBL8769203 | 0.83 | ACHE (0.63) | ACHETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-0945448-B1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-6414160-B1 | REACTING 5-ALKOXY-2(3H)OXAZOLONE COMPOUND WITH ALDEHYDE COMPOUND IN PRESENCE OF LEWIS ACID CATALYST | UBE INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1000937-A1 | PROCESS FOR PRODUCING 4-ALKOXYCARBONYL-2-OXAZOLIDINONE COMPOUNDS | UBE INDUSTRIES LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-6020496-A | 5-alkoxy-2(3H)-oxazolone compounds and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0945448-A1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ACHE 4434/4885ERN1 637/4885HRH4 1656/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | ACHE 4181/4885ERN1 3566/4885HRH4 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.